Zoledronic Acid

C.A.S.: [904894-54-8]

Process Patent AR P050103131 filed July, 2005 and WO 2007/16982. Drug Master File submitted to the FDA, European Regulatory Authorities and K-FDA (Korea). Manufacturing Process Audited and Approved by FDA (2011)
In house specifications. For further information contact us.

Sodium Ibandronate

C.A.S.: [138926-19-9]

Drug Master File submitted to the FDA, European Regulatory Authorities and K-FDA (Korea). Manufacturing Process Audited and Approved by K-FDA (2011). In house specifications. For further information contact us.

Sodium Alendronate

C.A.S.: [121268-17-5]

Drug Master File submitted to the FDA, European Regulatory Authorities and K-FDA (Korea). Specifications according to Ph. Eur. For further information contact us.

Pamidronic Acid

Drug Master File submitted to the FDA, TGA (Australia) and European Regulatory Authorities. Manufacturing Process Audited and Approved by FDA (2001, 2007 and 2011). In house specifications. For further information contact us.

Sodium Pamidronate

C.A.S.: [5724-88-1]

Process Patent AR 218.558 (june 13, 1980) .Specifications according to Ph. Eur.. For further information contact us.

Alprazolam

CAS: [28981-97-7]

Short Characteristics: Sedative

Specifications according to Eur. Ph.

For further information contact us.

Desvenlafaxine Succinate

CAS: [386750-22-7]

Short Characteristics: Antidepressant

In-house Specifications.

For further information contact us

Agomelatine

CAS: [138112-76-2]

Short Characteristics: Antidepressant

In-house Specifications.

For further information contact us.

Zaleplon

C.A.S.: [151319-34-5]

Process Patent AR P000106596 (Files December, 2000) and US 6.476.223 B2 (Novembre 5, 2002).
Drug Master File submitted to the FDA.
Manufacturing Process Audited and Approved by FDA (2007 and 2011)
In-house specifications.
For further information contact us.

Zolpidem Tartrate

C.A.S.: [99294-93-6]

Process Patent AR 255060.
Drug Master File submitted to the FDA and European Regulatory Authorities Manufacturing
Process Audited and Approved by Afssaps (France, 2007)
Specifications according to Ph. Eur.
For further information contact us.

Norelgestromin 18-Methyl-norethindrone oxime

CAS: [53016-31-2

Short Characteristics: Progestogen

Process Patent AR P 03 01 02267 (filed July,2003) and US 2004/0266741 A1

Drug Master File submitted to the FDA

In-house Specifications.

For further information contact us.

Nomegestrol Acetate

Short Characteristics: Progestogen

Specifications according to Eur. Ph.

For further information contact us.

Norgestimate (RO – CEP 2010-012-Rev 00)

C.A.S. R.N.: [35189-28-7]

Drug Master File submitted to the FDA
Manufacturing Process Audited and Approved by FDA (2007 and 2011)
Specifications according to USP and Ph. Eur.
For further information contact us.

Febuxostat

CAS: [144060-53-7]

Process Patent (USA) Application Number 61/39210 (October 14, 2010)
In-house Specifications.
For further information contact us.

Dutasteride

CAS: [164656-23-9]

Process Patent WO 2009/083258 A2 (Filed January, 2008).
Drug Master File submitted to the FDA.
In-house Specifications.
For further information contact us.

Plerixafor

CAS: [155148-31-5]

PIn-house Specifications.
For further information contact us

Mazindol

CAS: [22232-71-9]

Short Characteristics: Anorexic

Specifications according to USP.

For further information contact us.